[1]
|
Han, S.K., Baik, S.K. and Kim, M.Y. (2023) Non-Alcoholic Fatty Liver Disease: Definition and Subtypes. Clinical and Molecular Hepatology, 29, S5-S16. https://doi.org/10.3350/cmh.2022.0424
|
[2]
|
Rong, L., Zou, J., Ran, W., Qi, X., Chen, Y., Cui, H. and Guo, J, (2022) Advancements in the Treatment of Non-Alcoholic Fatty Liver Disease, (NAFLD). Frontiers in Endocrinology (Lausanne), 13, Article ID: 1087260.
https://doi.org/10.3389/fendo.2022.1087260
|
[3]
|
Zhou, J., Zhou, F., Wang, W., Zhang, X.-J., Ji, Y.-X., Zhang, P., She, Z.-G., Zhu, L., Cai, J. and Li, H. (2020) Epidemiological Features of NAFLD from 1999 to 2018 in China. Hepa-tology, 71, 1851-1864.
https://doi.org/10.1002/hep.31150
|
[4]
|
Sodhi, M., Rezaeianzadeh, R., Kezouh, A. and Etminan, M. (2023) Risk of Gastrointestinal Adverse Events Associated with Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA, 330, 1795-1797.
https://doi.org/10.1001/jama.2023.19574
|
[5]
|
Friedman, S.L., Neuschwander-Tetri, B.A., Rinella, M. and Sanyal, A.J. (2018) Mechanisms of NAFLD Development and Therapeutic Strategies. Nature Medicine, 24, 908-922. https://doi.org/10.1038/s41591-018-0104-9
|
[6]
|
Vuppalanchi, R., Noureddin, M., Alkhouri, N. and Sanyal, A.J. (2021) Therapeutic Pipeline in Nonalcoholic Steatohepatitis. Nature Reviews Gastroenterology & Hepatology, 18, 373-392. https://doi.org/10.1038/s41575-020-00408-y
|
[7]
|
Alkhouri, N., Herring, R., Kabler, H., Kayali, Z., Has-sanein, T., Kohli, A., Huss, R.S., Zhu, Y., Billin, A.N., Damgaard, L.H., Buchholtz, K., Kjær, M.S., Balendran, C., My-ers, R.P., Loomba, R. and Noureddin, M. (2022) Safety and Efficacy of Combination Therapy with Semaglutide, Ci-lofexor and Firsocostat in Patients with Non-Alcoholic Steatohepatitis: A Randomised, Open-Label Phase II Trial. Jour-nal of Hepatology, 77, 607-618.
https://doi.org/10.1016/j.jhep.2022.04.003
|
[8]
|
Song, S., Xiao, Z., Dekker, F.J., Poelarends, G.J. and Melgert, B.N. (2022) Macrophage Migration Inhibitory Factor Family Proteins Are Multitasking Cytokines in Tissue Injury. Cellular and Molecular Life Sciences, 79, Article No. 105. https://doi.org/10.1007/s00018-021-04038-8
|
[9]
|
Leng, L., Metz, C.N., Fang, Y., Xu, J., Donnelly, S., Baugh, J., Delohery, T., Chen, Y., Mitchell, R.A. and Bucala, R. (2003) MIF Sig-nal Transduction Initiated by Binding to CD74. Journal of Experimental Medicine, 197, 1467-1476.
https://doi.org/10.1084/jem.20030286
|
[10]
|
Barnes, M.A., McMullen, M.R., Roychowdhury, S., Pisano, S.G., Liu, X., Stavitsky, A.B., Bucala, R. and Nagy, L.E. (2013) Macrophage Migration Inhibitory Factor Contributes to Etha-nol-Induced Liver Injury by Mediating Cell Injury, Steatohepatitis, and Steatosis. Hepatology, 57, 1980-1991. https://doi.org/10.1002/hep.26169
|
[11]
|
Bernhagen, J., Krohn, R., Lue, H., Gregory, J.L., Zernecke, A., Koenen, R.R., Dewor, M., Georgiev, I., Schober, A., Leng, L., Kooistra, T., Fingerle-Rowson, G., Ghezzi, P., Kleemann, R., McColl, S.R., Bucala, R., Hickey, M.J. and Weber, C. (2007) MIF Is a Noncognate Ligand of CXC Chemokine Recep-tors in Inflammatory and Atherogenic Cell Recruitment. Nature Medicine, 13, 587-596. https://doi.org/10.1038/nm1567
|
[12]
|
Su, H., Na, N., Zhang, X. and Zhao, Y. (2017) The Biological Function and Significance of CD74 in Immune Diseases. Inflammation Research, 66, 209-216. https://doi.org/10.1007/s00011-016-0995-1
|
[13]
|
Lue, H., Thiele, M., Franz, J., Dahl, E., Speckgens, S., Leng, L., Fingerle-Rowson, G., Bucala, R., Lüscher, B. and Bernhagen, J. (2007) Macrophage Migration Inhibitory Factor, (MIF) Promotes Cell Survival by Activation of the Akt Pathway and Role for CSN5/JAB1 in the Control of Autocrine MIF Activity. Oncogene, 26, 5046-5059.
https://doi.org/10.1038/sj.onc.1210318
|
[14]
|
Shi, X., Leng, L., Wang, T., Wang, W., Du, X., Li, J., McDonald, C., Chen, Z., Murphy, J.W., Lolis, E., Noble, P., Knudson, W. and Bucala, R. (2006) CD44 Is the Signaling Component of the Macrophage Migration Inhibitory Factor-CD74 Receptor Complex. Immunity, 25, 595-606. https://doi.org/10.1016/j.immuni.2006.08.020
|
[15]
|
Mitchell, R.A., Metz, C.N., Peng, T. and Bucala, R. (1999) Sustained Mitogen-Activated Protein Kinase, (MAPK) and Cytoplasmic Phospholipase A2 Activation by Macrophage Migration Inhibitory Factor, (MIF). Regulatory Role in Cell Proliferation and Glucocorticoid Action. Journal of Biologi-cal Chemistry, 274, 18100-18106.
https://doi.org/10.1074/jbc.274.25.18100
|
[16]
|
Mitchell, R.A., Liao, H., Chesney, J., Fingerle-Rowson, G., Baugh, J., David, J. and Bucala, R. (2002) Macrophage Migration Inhibitory Factor, (MIF) Sustains Macrophage Proinflamma-tory Function by Inhibiting P53: Regulatory Role in the Innate Immune Response. Proceedings of the National Academy of Sciences of the United States of America, 99, 345-350. https://doi.org/10.1073/pnas.012511599
|
[17]
|
Bach, J.-P., Rinn, B., Meyer, B., Dodel, R. and Bacher, M. (2008) Role of MIF in Inflammation and Tumorigenesis. Oncology, 75, 127-133. https://doi.org/10.1159/000155223
|
[18]
|
Weber, C., Kraemer, S., Drechsler, M., Lue, H., Koenen, R.R., Kapurniotu, A., Zernecke, A. and Bernhagen, J. (2008) Structural Determinants of MIF Functions in CXCR2-Mediated Inflammatory and Atherogenic Leukocyte Recruitment. Proceedings of the National Academy of Sciences of the United States of America, 105, 16278-16283.
https://doi.org/10.1073/pnas.0804017105
|
[19]
|
Morrison, M.C. and Kleemann, R. (2015) Role of Macrophage Mi-gration Inhibitory Factor in Obesity, Insulin Resistance, Type 2 Diabetes, and Associated Hepatic Co-Morbidities: A Comprehensive Review of Human and Rodent Studies. Frontiers in Immunology, 6, Article No. 308. https://doi.org/10.3389/fimmu.2015.00308
|
[20]
|
Chan, P.-C., Wu, T.-N., Chen, Y.-C., Lu, C.-H., Wabitsch, M., Tian, Y.-F. and Hsieh, P.-S. (2018) Targetted Inhibition of CD74 Attenuates Adipose COX-2-MIF-Mediated M1 Mac-rophage Polarization and Retards Obesity-Related Adipose Tissue Inflammation and Insulin Resistance. Clinical Science (London), 132, 1581-1596.
https://doi.org/10.1042/CS20180041
|
[21]
|
Finucane, O.M., Reynolds, C.M., McGillicuddy, F.C., Harford, K.A., Morrison, M., Baugh, J. and Roche, H.M. (2014) Macrophage Migration Inhibitory Factor Deficiency Ameliorates High-Fat Diet Induced Insulin Resistance in Mice with Reduced Adipose Inflammation and Hepatic Steatosis. PLOS ONE, 9, e113369.
https://doi.org/10.1371/journal.pone.0113369
|
[22]
|
Alvehus, M., Burén, J., Sjöström, M., Goedecke, J. and Olsson, T. (2010) The Human Visceral Fat Depot Has a Unique Inflammatory Profile. Obesity (Silver Spring), 18, 879-883. https://doi.org/10.1038/oby.2010.22
|
[23]
|
Verschuren, L., Kooistra, T., Bernhagen, J., Voshol, P.J., Ouwens, D.M., Van Erk, M., De Vries-Van, Der Weij, J., Leng, L., Van Bockel, J.H., Van Dijk, K.W., Fingerle-Rowson, G., Bucala, R. and Kleemann, R. (2009) MIF Deficiency Reduces Chronic Inflammation in White Adipose Tissue and Impairs the De-velopment of Insulin Resistance, Glucose Intolerance, and Associated Atherosclerotic Disease. Circulation Research, 105, 99-107.
https://doi.org/10.1161/CIRCRESAHA.109.199166
|
[24]
|
Conine, S.J. and Cross, J.V. (2014) MIF Deficiency Does Not Alter Glucose Homeostasis or Adipose Tissue Inflammatory Cell Infiltrates During Diet-Induced Obesity. Obesity (Silver Spring), 22, 418-425.
https://doi.org/10.1002/oby.20555
|
[25]
|
Akyildiz, M., Gunsar, F., Nart, D., Sahin, O., Yilmaz, F., Akay, S., Ersoz, G., Karasu, Z., Ilter, T., Batur, Y., Berdeli, A. and Akarca, U. (2010) Macrophage Migration Inhibitory Factor Expres-sion and MIF Gene-173 G/C Polymorphism in Nonalcoholic Fatty Liver Disease. European Journal of Gastroenterolo-gy & Hepatology, 22, 192-198.
https://doi.org/10.1097/MEG.0b013e328331a596
|
[26]
|
Moon, H.Y., Song, P., Choi, C.S., Ryu, S.H. and Suh, P.-G. (2013) Involvement of Exercise-Induced Macrophage Migration Inhibitory Factor in the Prevention of Fatty Liver Disease. Journal of Endocrinology, 218, 339-348.
https://doi.org/10.1530/JOE-13-0135
|
[27]
|
Hu, M., Zhang, D., Xu, H., Zhang, Y., Shi, H., Huang, X., Wang, X., Wu, Y. and Qi, Z. (2021) Salidroside Activates the AMP-Activated Protein Kinase Pathway to Suppress Nonalcoholic Steatohepatitis in Mice. Hepatology, 74, 3056- 3073. https://doi.org/10.1002/hep.32066
|
[28]
|
You, B., Dun, Y., Fu, S., Qi, D., Zhang, W., Liu, Y., Qiu, L., Xie, M. and Liu, S. (2021) The Treatment of Rhodiola Mimics Exercise to Resist High-Fat Diet-Induced Muscle Dysfunction via Sirtuin1-Dependent Mechanisms. Frontiers in Pharmacology, 12, Arti-cle ID: 646489. https://doi.org/10.3389/fphar.2021.646489
|
[29]
|
Heinrichs, D., Brandt, E.F., Fischer, P., Köhncke, J., Wirtz, T.H., Guldiken, N., Djudjaj, S., Boor, P., Kroy, D., Weiskirchen, R., Bucala, R., Wasmuth, H.E., Strnad, P., Trautwein, C., Bernhagen, J. and Berres, M.-L. (2021) Unexpected Pro-Fibrotic Effect of MIF in Non-Alcoholic Steato-hepatitis Is Linked to a Shift in NKT Cell Populations. Cells, 10, Article No. 252. https://doi.org/10.3390/cells10020252
|
[30]
|
Park, O., Jeong, W.-I., Wang, L., Wang, H., Lian, Z.-X., Gershwin, M.E. and Gao, B. (2009) Diverse Roles of Invariant Natural Killer T Cells in Liver Injury and Fibrosis Induced by Car-bon Tetrachloride. Hepatology, 49, 1683-1694.
https://doi.org/10.1002/hep.22813
|
[31]
|
Syn, W.-K., Agboola, K.M., Swiderska, M., Michelotti, G.A., Liaskou, E., Pang, H., Xie, G., Philips, G., Chan, I.S., Karaca, G.F., Pereira, T.A., Chen, Y., Mi, Z., Kuo, P.C., Choi, S.S., Guy, C.D., Abdelmalek, M.F. and Diehl, A.M. (2012) NKT-Associated Hedgehog and Osteopontin Drive Fibrogenesis in Non-Alcoholic Fatty Liver Disease. Gut, 61, 1323-1329. https://doi.org/10.1136/gutjnl-2011-301857
|
[32]
|
Kumar, V. (2013) NKT-Cell Subsets: Promoters and Protectors in Inflammatory Liver Disease. Journal of Hepatology, 59, 618-620. https://doi.org/10.1016/j.jhep.2013.02.032
|
[33]
|
Heinrichs, D., Berres, M.-L., Coeuru, M., Knauel, M., Nellen, A., Fischer, P., Philippeit, C., Bucala, R., Trautwein, C., Wasmuth, H.E. and Bernhagen, J. (2014) Protective Role of Macrophage Migration Inhibitory Factor in Nonalcoholic Steatohepatitis. The FASEB Journal, 28, 5136-5147. https://doi.org/10.1096/fj.14-256776
|
[34]
|
Heinrichs, D., Knauel, M., Offermanns, C., Berres, M.-L., Nellen, A., Leng, L., Schmitz, P., Bucala, R., Trautwein, C., Weber, C., Bernhagen, J. and Wasmuth, H.E. (2011) Macrophage Mi-gration Inhibitory Factor, (MIF) Exerts Antifibrotic Effects in Experimental Liver Fibrosis via CD74. Proceedings of the National Academy of Sciences of the United States of America, 108, 17444-17449. https://doi.org/10.1073/pnas.1107023108
|
[35]
|
Thuy, L.T.T. and Kawada, N. (2012) Antifibrotic Role of Macro-phage Migration Inhibitory Factor: Discovery of an Unexpected Function. Hepatology, 55, 1295-1297. https://doi.org/10.1002/hep.25605
|